News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eli Lilly and Company (LLY) Trials Boost Amyloid Link to Alzheimer's in Two Phase 3 Studies


10/30/2012 7:36:54 AM

Levels of a protein believed to be a main cause of Alzheimer's disease rose in the blood of patients treated with Eli Lilly's experimental drug in late-stage trials, suggesting the protein, beta amyloid, was removed from the brain as intended, researchers said on Monday.

Lilly in August disclosed that its drug solanezumab did not significantly arrest progression of the memory-robbing disease in the pair of Phase III studies, which tested patients with mild to moderate symptoms of Alzheimer's.

Read at Fox News


comments powered by Disqus
Fox News
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES